CHA Biotech said that it has obtained a patent for the use of placenta-derived mesenchymal stem cell lines.
By acquiring the patent, the company has secured the right to develop treatments for degenerative neurological diseases using placental-derived mesenchymal stem cells.
Compared to existing adult stem cells, the company's placenta-derived mesenchymal stem cells contain various therapeutic efficacies that directly affect brain damage and neuroinflammation, which can help treat Alzheimer's and Lou Gehrig's disease.
Currently, the company is developing Plastem-AD, an Alzheimer's drug, and is conducting a phase 1 and 2a clinical trials in Korea. With the acquisition of the patent, CHA Biotech plans to accelerate clinical trials further.
"The patent will accelerate ongoing clinical trials and expand the application of placental-derived mesenchymal stem cells to various degenerative neurological diseases in addition to Alzheimer's disease," CHA Biotech CEO Oh Sang-hoon said.
The company plans to commercialize cell therapy products optimized for rare and intractable diseases as soon as possible, Oh added.